MacarenaInesDe La FuenteMD

PubMed

• 1 citations
  Delineation of recurrent glioblastoma by whole brain spectroscopic magnetic resonance imaging.
  Jonathan B Bell, William Jin, Mohammed Z Goryawala, Gregory A Azzam, Matthew C Abramowitz, Tejan Diwanji, Michael E Ivan, Maria Del Pilar Guillermo Prieto Eibl, Macare...> ;Radiation Oncology. 2023 Feb 22
• 1 citations
  A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma.
  Karthik K Ramesh, Vicki Huang, Jeffrey Rosenthal, Eric A Mellon, Mohammed Goryawala, Peter B Barker, Saumya S Gurbani, Anuradha G Trivedi, Alexander S Giuffrida, Eduar...> ;Tomography. 2023 Feb 6
• 7 citations
  Targeting IDH1/IDH2 mutations in gliomas.
  Macarena I de la Fuente> ;Current Opinion in Neurology. 2022 Dec 1
• 4 citations
  Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma.
  Vaidya Govindarajan, Ashish H Shah, Sarah Rivas, Robert K Suter, Daniel G Eichberg, Evan Luther, Victor Lu, Alexis A Morell, Michael E Ivan, Ricardo J Komotar, Nagi Ay...> ;World Neurosurgery. 2022 Jun 1
• 21 citations
  Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
  Macarena I de la Fuente, Howard Colman, Mark Rosenthal, Brian A Van Tine, Danijela Levacic, Tobias Walbert, Hui K Gan, Maria Vieito, Mohammed M Milhem, Kathryn Lipford...> ;Neuro-Oncology. 2023 Jan 5
• 15 citations
  A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma.
  Karthik Ramesh, Eric A Mellon, Saumya S Gurbani, Brent D Weinberg, Eduard Schreibmann, Sulaiman A Sheriff, Mohammed Goryawala, Macarena de le Fuente, Bree R Eaton, Jim...> ;Neuro-Oncology Advances. 2022 Jan 27
• 1 citations
  Factors associated with the use of salvage whole brain radiation therapy versus salvage stereotactic radiosurgery after initial stereotactic radiosurgery for brain met...
  Yash S Soni, Benjamin J Rich, Deukwoo Kwon, Wei Zhao, Danny L John, Jessica Meshman, Ronald Benveniste, Ricardo J Komotar, Macarena de la Fuente, Maria Del Pilar Guill...> ;Journal of Radiosurgery and SBRT. 2022 Jan 1
• A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell lines.
  Ashish H Shah, Robert Suter, Pavan Gudoor, Tara T Doucet-O'Hare, Vasileios Stathias, Iahn Cajigas, Macarena de la Fuente, Vaidya Govindarajan, Alexis A Morell, Daniel ...> ;Neuro-Oncology Advances. 2021 Dec 31
• 1 citations
  Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial.
  Corinne E Griguer, Claudia R Oliva, Christopher S Coffey, Merit E Cudkowicz, Robin A Conwit, Anna L Gudjonsdottir, Dixie J Ecklund, Janel K Fedler, Tina M Neill-Hudson...> ;Neuro-Oncology Advances. 2021 Dec 24
• 5 citations
  SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology
  Ugonma Chukwueke, Elizabeth Vera, Alvina Acquaye, Shawn L. Hervey-Jumper, Yazmin Odia, Laura J. Klesse, Erin M. Dunbar, Akanksha Sharma, Ekokobe Fonkem, Alissa A. Thom...> ;Neuro-Oncology. 2021 Nov 2
• 82 citations
  Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
  Ingo K. Mellinghoff, Marta Penas-Prado, Katherine B. Peters, Howard A. Burris, Elizabeth A. Maher, Filip Janku, Gregory M. Cote, Macarena I. de la Fuente, Jennifer Cla...> ;Clinical Cancer Research. 2021 Aug 15
• 3 citations
  Emergent Radiotherapy for Leukemia-Induced Cranial Neuropathies Refractory to Intrathecal Therapy
  Nirav V. Patel, Benjamin J. Rich, Shareen Patel, Justin M. Watts, Ronald J. Benveniste, Matthew C. Abramowitz, Arnold M. Markoe, Daniel G Eichberg, Ricardo J. Komotar,...> ;Cureus. 2021 May 24
• 13 citations
  Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
  Mustafa Khasraw, Michael Weller, David Lorente, Kathryn Kolibaba, Chee Khoon Lee, Craig Gedye, Macarena I. de la Fuente, David Vicente, David A. Reardon, Hui K Gan, An...> ;Neuro-Oncology Advances. 2021 Jan 1
• 19 citations
  Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study.
  Dalissa Tejera, Marina Kushnirsky, Sakir H. Gultekin, Min Lu, Lori Steelman, Macarena I. de la Fuente> ;CNS Oncology. 2020 Sep 1
• 36 citations
  Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection
  Ashish H. Shah, Anil K. Mahavadi, Long Di, Alexander D. Sanjurjo, Daniel G Eichberg, Veronica Borowy, Javier Figueroa, Evan Luther, Macarena I. de la Fuente, Alexa Sem...> ;Journal of Neuro-Oncology. 2020 Jul 5
• 124 citations
  Ivosidenib in Isocitrate Dehydrogenase 1 - Mutated Advanced Glioma.
  Ingo K. Mellinghoff, Benjamin M. Ellingson, Mehdi Touat, Elizabeth A. Maher, Macarena I. de la Fuente, Matthias Holdhoff, Gregory M. Cote, Howard A. Burris, Filip Jank...> ;Journal of Clinical Oncology. 2020 Jun 12
• 1 citations
  Central nervous system emergencies in haematological malignancies
  Macarena I. de la Fuente, Juan Pablo Alderuccio, Izidore S. Lossos> ;British Journal of Haematology. 2020 Jun 1
• 18 citations
  Resection versus biopsy in the treatment of multifocal glioblastoma: a weighted survival analysis
  Long Di, Rainya N. Heath, Ashish H. Shah, Alexander D. Sanjurjo, Daniel G Eichberg, Evan Luther, Macarena I. de la Fuente, Ricardo J. Komotar, Michael E. Ivan> ;Journal of Neuro-Oncology. 2020 May 11
• 3 citations
  Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicine.
  Macarena I. de la Fuente, Marc K. Rosenblum, Eli L. Diamond, Viviane Tabar, Antonio Omuro> ;Neurology(R) Neuroimmunology & Neuroinflammation. 2020 Mar 2
• 21 citations
  Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma
  Marina Kushnirsky, Lynn G. Feun, Sakir H. Gultekin, Macarena I. de la Fuente> ;JCO Precision Oncology. 2020 Feb 3
• 69 citations
  Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
  Lillian M. Smyth, Sarina Anne Piha-Paul, Helen Won, Alison M. Schram, Cristina Saura, Sherene Loi, Janice Lu, Geoffrey I. Shapiro, Dejan Juric, Ingrid A. Mayer, Carlos...> ;Cancer Discovery. 2020 Feb 1
• 22 citations
  Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation.
  Juan Pablo Alderuccio, Wei Zhao, Amrita Desai, Jeremy Ramdial, Nicolas Gallastegui, Erik Kimble, Macarena I. de la Fuente, Muhammad Husnain, Joseph D. Rosenblatt, Alva...> ;American Journal of Hematology. 2019 May 1
• 14 citations
  Bilateral radiation therapy followed by methotrexate‐based chemotherapy for primary vitreoretinal lymphoma
  Macarena I. de la Fuente, Juan Pablo Alderuccio, Isildinha M. Reis, Antonio Omuro, Arnold M. Markoe, Jose J. Echegaray, Janet L. Davis, J. William Harbour, Izidore S. ...> ;American Journal of Hematology. 2019 Apr 1
• 10 citations
  Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.
  Christopher Chin, Emma S. Lunking, Macarena I. de la Fuente, Nagi G. Ayad> ;Frontiers in Oncology. 2018 Nov 13
• 42 citations
  Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution
  Juan Pablo Alderuccio, Wei Zhao, Amrita Desai, Nicolas Gallastegui, Jeremy Ramdial, Erik Kimble, Macarena I. de la Fuente, Joseph D. Rosenblatt, Jennifer R. Chapman, F...> ;Journal of Clinical Oncology. 2018 Oct 12
• Join now to see all